Open AccessYttrium-90-Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy after Cytoreduction with ESHAP Chemotherapy in Patients with Relapsed Follicular Non-Hodgkin Lymphoma: Final Results of a Phase II Study
Author(s) -
Soham D. Puvvada,
José Guillen-Rodriguez,
Jessica Yan,
Lora Inclán,
Kara Heard,
Xavier Rivera,
Faiz Anwer,
Daruka Mahadevan,
Jonathan H. Schatz,
Daniel Persky
Publication year - 2018
Publication title -
oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.987
H-Index - 98
eISSN - 1423-0232
pISSN - 0030-2414
DOI - 10.1159/000486788
Subject(s) - medicine , ibritumomab tiuxetan , follicular lymphoma , radioimmunotherapy , international prognostic index , surgery , progressive disease , debulking , neutropenia , etoposide , oncology , rituximab , lymphoma , chemotherapy , cancer , ovarian cancer , immunology , monoclonal antibody , antibody
Radioimmunotherapy (RIT) is effective in treating relapsed/refractory follicular lymphoma (FL), with durable remissions in first-line consolidation. We hypothesized that RIT with ibritumomab tiuxetan (Zevalin®) would result in durable remissions by eliminating minimal residual disease after cytoreduction.